marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-08-2024
Moleculin Biotech Balance Sheet 2011-2024 | MBRX
Annual Balance Sheet Moleculin Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-23.1 M | -42.8 M | -70.8 M | -14.9 M | -10.4 M | -7.13 M | -7.71 M | -4.71 M | 422 K | - | - | - | - |
Long Term Debt |
474 K | 335 K | 63 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | 103 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 8.35 M | 6.09 M | 1.44 M | 150 K | 87.5 K | - | - | - | - | - |
Total Current Liabilities |
6.82 M | 4.82 M | 3.62 M | 2.92 M | 3.57 M | 3.88 M | 2.22 M | 1.35 M | - | - | - | - | - |
Total Liabilities |
12.1 M | 5.23 M | 5.1 M | 11.3 M | 9.66 M | 5.31 M | 2.36 M | 1.43 M | 773 K | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-132 M | -102 M | -72.8 M | -56.9 M | -39.6 M | -26.4 M | -14.5 M | -4.67 M | -748 K | - | - | - | - |
Total Assets |
38.2 M | 57.4 M | 84.1 M | 29 M | 25.2 M | 19.6 M | 19.5 M | 16.4 M | 28.1 K | - | - | - | - |
Cash and Cash Equivalents |
23.6 M | 43.1 M | 70.9 M | 15.2 M | 10.7 M | 7.13 M | 7.71 M | 5.01 M | 28.1 K | - | - | - | - |
Book Value |
26.1 M | 52.2 M | 79 M | 17.8 M | 15.6 M | 14.3 M | 17.1 M | 15 M | -745 K | - | - | - | - |
Total Shareholders Equity |
26.1 M | 52.2 M | 79 M | 17.8 M | 15.6 M | 14.3 M | 17.1 M | 15 M | -745 K | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Moleculin Biotech
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
390 K | 420 K | 474 K | 496 K | 291 K | 308 K | 335 K | 365 K | 388 K | 50 K | 63 K | 75 K | 94 K | 127 K | 159 K | 159 K | 159 K | 159 K | 276 K | 276 K | 276 K | 276 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
15.9 M | 7.87 M | 12.1 M | 4.38 M | 6.85 M | 5.38 M | 5.23 M | 6.96 M | 6.9 M | 6.14 M | 5.1 M | 7.44 M | 8.83 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 9.66 M | 9.66 M | 9.66 M | 9.66 M | 5.31 M | 5.31 M | 5.31 M | 5.31 M | 2.36 M | 2.36 M | 2.36 M | 2.36 M | 1.43 M | 1.43 M | 1.43 M | 1.43 M | 773 K | 773 K | 773 K | 773 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-151 M | -141 M | -132 M | -121 M | -116 M | -110 M | -102 M | -95.1 M | -86.5 M | -79.7 M | -72.8 M | -70 M | -65.6 M | -61.4 M | -56.9 M | -56.9 M | -56.9 M | -56.9 M | -39.6 M | -39.6 M | -39.6 M | -39.6 M | -26.4 M | -26.4 M | -26.4 M | -26.4 M | -14.5 M | -14.5 M | -14.5 M | -14.5 M | -4.68 M | -4.68 M | -4.68 M | -4.68 M | -748 K | -748 K | -748 K | -748 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
23.4 M | 25.6 M | 38.2 M | 39.5 M | 47.1 M | 51.1 M | 57.4 M | 65.4 M | 73.3 M | 78.8 M | 84.1 M | 88.7 M | 93.5 M | 99.8 M | 29 M | 29 M | 29 M | 29 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 28.1 K | 28.1 K | 28.1 K | 28.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
9.4 M | 10.8 M | 23.6 M | 24.6 M | 32.2 M | 37.3 M | 43.1 M | 50.4 M | 58 M | 66.1 M | 70.9 M | 75.2 M | 79.5 M | 86.3 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 7.13 M | 7.13 M | 7.13 M | 7.13 M | 7.71 M | 7.71 M | 7.71 M | 7.71 M | 5.01 M | 5.01 M | 5.01 M | 5.01 M | 28 K | 28.1 K | 28.1 K | 28.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
7.48 M | 17.7 M | 26.1 M | 35.1 M | 40.3 M | 45.7 M | 52.2 M | 58.4 M | 66.4 M | 72.7 M | 79 M | 81.3 M | 84.7 M | 88.5 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 15 M | 15 M | 15 M | 15 M | -745 K | -745 K | -745 K | -745 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
7.48 M | 17.7 M | 26.1 M | 35.1 M | 40.3 M | 45.7 M | 52.2 M | 58.4 M | 66.4 M | 72.7 M | 79 M | 81.3 M | 84.7 M | 88.5 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 15 M | 15 M | 15 M | 15 M | -745 K | -745 K | -745 K | -745 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency